The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- Foundation for Sarcoidosis Research Announces 13 Inaugural Sites for Groundbreaking FSR Clinical Data Registry
- FSR Invests $700,000 Across Four Sarcoidosis Studies
- FSR Announces New Partnership with Patient Advocate Foundation to Expand Insurance and Disability Support for Sarcoidosis Patients
- Powering Sarcoidosis Advocacy: FSR at ATS 2026
- Living with Sarcoidosis: A Family Story of Strength and Awareness